tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Citius Pharmaceuticals Closes $6M Securities Offering

Story Highlights
Citius Pharmaceuticals Closes $6M Securities Offering

Elevate Your Investing Strategy:

An update from Citius Pharmaceuticals ( (CTXR) ) is now available.

On June 9, 2025, Citius Pharmaceuticals entered into a securities purchase agreement with an institutional investor for a registered direct offering of common stock and pre-funded warrants, closing on June 11, 2025. The offering, facilitated by H.C. Wainwright & Co., raised approximately $6 million in gross proceeds, with net proceeds expected to support the commercial launch of LYMPHIR and other corporate purposes. The issuance included warrants exercisable at $1.00 per share, with potential additional proceeds of $9.8 million if fully exercised. The company agreed to restrictions on issuing additional shares for 60 days post-closing, with certain exceptions.

The most recent analyst rating on (CTXR) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Citius Pharmaceuticals stock, see the CTXR Stock Forecast page.

Spark’s Take on CTXR Stock

According to Spark, TipRanks’ AI Analyst, CTXR is a Underperform.

Citius Pharmaceuticals’ overall stock score reflects the challenging financial performance and bearish technical indicators. The company’s ongoing losses, reliance on external financing, and negative cash flows are significant concerns. The stock’s downward momentum and negative valuation metrics further contribute to the low score. The biotech firm remains speculative, hinging on future revenue generation and operational improvements.

To see Spark’s full report on CTXR stock, click here.

More about Citius Pharmaceuticals

Citius Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing first-in-class critical care products. The company’s product portfolio includes LYMPHIR, an FDA-approved targeted immunotherapy for cutaneous T-cell lymphoma, Mino-Lok, an antibiotic lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief.

Average Trading Volume: 2,050,595

Technical Sentiment Signal: Sell

Current Market Cap: $10.91M

See more data about CTXR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1